Background: Paclitaxel and docetaxel are considered fundamental drugs in the treatment of breast cancer.
Objectives: To review the current role of taxanes in the treatment breast cancer, with emphasis on data from randomized trials comparing the two taxanes.
Methods: We have reviewed the available evidence in the literature to gauge the results of therapy of early and advanced breast cancer with taxanes.
Results: Clinically benefits were first shown in metastatic setting. More recently, benefits have also been seen in the therapy of early-stage disease. It seems reasonable to consider either drug as standard treatment for node-positive early stage or metastatic breast cancer. Future studies should explore the optimal way of combining taxanes with novel biological and cytotoxic drugs.
Conclusion: Based on existing evidence, clinicians should choose a taxane-based regimen for their patients, according to clinical activity, toxicity profile, pharmacokinetics, and a dosing schedule that best meets the therapeutic needs and convenience.